Effects of Sodium Glucose Cotransporter-2 Inhibitors on Hemodynamics and Sympathetic System in Obesity-Related Hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032391

Enrollment

Unknown

Registered

2020-04-27

Start date

2020-05-01

Completion date

Unknown

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

experimental group:dagglitazine 10mg qd

control group:amlodipine 5mg qd

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged >= 35 years; 2. Mild or moderate primary hypertension (SBP at 150-179 mmHg and / or DBP at 95-109 mmHg) without complications; 3. BMI >= 30 kg / m2; 4. No antihypertensive drugs used; 5. Did not participate in other clinical GCP studies; 6. Agree and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. BMI >= 40 kg / m2; 2. Liver and kidney dysfunction; 3. Serious complications of heart, brain and kidney; 4. Diabetes; 5. Secondary or malignant hypertension; 6. Intolerance to perindopril, amlodipine OR dagglitazine; 7. Drug or alcohol abuse; 8. Pregnancy or breastfeeding.

Design outcomes

Primary

Measure	Time frame
height;weight;waistline;hipline;ECG;Consulting room blood pressure;Ambulatory blood pressure;Noradrenaline;renin;Angiotensin;Aldosterone;Fasting blood glucose;Postprandial glucose;Fasting insulin;Postprandial insulin;Blood lipid;Uric acid;Electrolyte;Glycosylated hemoglobin;	—

Countries

China

Contacts

Public ContactKai Liu

Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

297300058@qq.com+86 15682073658

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026